CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial When high‐volume PCI operators in high‐volume hospitals move to lower volume hospitals—Do they still maintain high volume and quality of outcomes? Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Appropriate Use Criteria and Health Status Outcomes Following Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the OPEN-CTO Registry 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Chronic Total Occlusion Percutaneous Coronary Intervention: Evidence and Controversies Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Original Research

JOURNAL:Eur Heart J. Article Link

Systemic microvascular dysfunction in microvascular and vasospastic angina

Ford TJ, Rocchiccioli P, Good R et al. Keywords: coronary microvascular dysfunction; vasospasm; ischaemia with no obstructive coronary artery disease; peripheral small artery; microvascular angina; vasospastic angina; endothelin-1; endothelial dysfunction; vasoconstriction

FULL TEXT PDF